Sylvie Peraldi Roux is Director of Research at the CNRS. She got her PhD in Neuroendocrinology at Montpellier Faculty of Science in 1990. After a postdoc at the Max Plant Institute in Munich, on Antibody Engineering, she got a permanent position at the CNRS in 1993, where she developed new methodologies: “Human in cell PCR”, which she used to create human antibody libraries by phage display, and to study human antibodies repertoire in autoimmune thyroid diseases. Her work is progressively focusing on the physiophatology of type 2 diabetes. In 2016, she moved to the “Institute des Biomolecules Max Mousseron” (CNRS, Montpellier) and joined the RCPG Cellular Pharmacology team where she is now studying the anti-diabetic activity of Ghrelin Receptor Ligands. Her work, at the interface of chemistry and biology of the ghrelin system, aims to study the protective effects and mechanism of action of novel synthetic analogues of the ghrelin family to protect/restore pancreatic cell functionality.